

PROFESSIONAL INFORMATION

SCHEDULING STATUS

S4

1 NAME OF THE MEDICINE

MYLAMBA 600 mg/300 mg Film-coated tablets

WARNING:

LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, INCLUDING FATAL CASES, HAVE BEEN REPORTED WITH THE USE OF NUCLEOSIDE ANALOGUES ALONE OR IN COMBINATION WITH OTHER ANTIRETROVIRALS (SEE WARNINGS).

Hypersensitivity Reaction:

Skin patch testing has no utility in the clinical management of patients and therefore should not be used in the clinical setting.

Before initiating treatment with MYLAMBA, screening for carriage of the HLA-B*5701 allele should be performed. DUMIVA should not be used in patients known to carry the HLA-B*5701 allele.

In clinical studies approximately 5 % of subjects receiving abacavir developed a hypersensitivity reaction. Some of these cases were life-threatening and resulted in a fatal outcome despite taking precautions.

Studies have shown that carriage of the HLA-B*5701 allele is associated with a more than 50 % increased risk of a hypersensitivity reaction to abacavir.

Abacavir should not be used in patients known to carry the HLA-B*5701

allele, unless no other therapeutic option is available based on the treatment history and resistance testing.

In any patient treated with MYLAMBA, the clinical diagnosis of suspected hypersensitivity reaction must remain the basis of clinical decision-making.

Even in the absence of HLA-B*5701 allele, it is important to permanently discontinue MYLAMBA and not rechallenge with MYLAMBA or abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.

• **Clinical Description**

Hypersensitivity reactions are characterised by the appearance of symptoms indicating multi-organ system involvement. Almost all hypersensitivity reactions will have fever and/or rash as part of the syndrome.

Other signs and symptoms may include respiratory signs and symptoms such as dyspnoea, sore throat, cough, and abnormal chest x-ray findings (predominantly infiltrates, which can be localised), gastrointestinal symptoms, such as nausea, vomiting, diarrhoea, or abdominal pain, and may lead to misdiagnosis of hypersensitivity as respiratory disease (pneumonia, bronchitis, pharyngitis), or gastroenteritis. Other frequently observed signs or symptoms of the hypersensitivity reaction may include lethargy or malaise and musculoskeletal symptoms (myalgia, rarely myolysis, arthralgia).

The symptoms related to this hypersensitivity reaction worsen with continued therapy and can be life threatening. These symptoms usually resolve upon discontinuation of MYLAMBA.

• **Clinical Management**

Hypersensitivity reaction symptoms usually appear within the first six weeks of initiation of treatment with MYLAMBA, although these reactions may occur at any time during therapy. Patients should be monitored closely, especially during the first two months of treatment with MYLAMBA, with consultation every two weeks.

Patients who are diagnosed with a hypersensitivity reaction whilst on therapy **MUST** discontinue the fixed-dose combination of MYLAMBA tablets immediately.

The fixed-dose combination of MYLAMBA tablets, or any other medicinal product containing abacavir, **MUST NEVER** be restarted in patients who have stopped therapy due to a hypersensitivity reaction.

Restarting MYLAMBA, or other medicines containing abacavir following a hypersensitivity reaction, results in a prompt return of symptoms within hours. This recurrence is usually more severe than on initial presentation and may include life-threatening hypotension and death.

To avoid a delay in diagnosis and minimise the risk of a life-threatening hypersensitivity reaction, the fixed-dose combination of MYLAMBA tablets must be permanently discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible (respiratory diseases, flu-like illness, gastroenteritis or reactions to other medicinal products).

Special care is needed for those patients simultaneously starting treatment with the fixed-dose combination of MYLAMBA tablets and other medicinal products known to induce skin toxicity (such as nucleotide and non-

nucleoside reverse transcriptase inhibitors - NNRTIs). This is because it is currently difficult to differentiate between rashes induced by these products and abacavir related hypersensitivity reactions.

- Management after an interruption of the fixed-dose combination of MYLAMBA tablets therapy.

If therapy with the fixed-dose combination of MYLAMBA tablets has been discontinued for any reason and restarting therapy is under consideration, the reason for discontinuation must be established to assess whether the patient had any symptoms of a hypersensitivity reaction. If a hypersensitivity reaction cannot be ruled out, the fixed-dose combination of MYLAMBA or any other medicinal product containing abacavir must not be restarted.

Hypersensitivity reactions with rapid onset, including life-threatening reactions have occurred after restarting abacavir in patients who had only one of the key symptoms of hypersensitivity (skin rash, fever, gastrointestinal, respiratory or constitutional symptoms such as lethargy and malaise) prior to stopping abacavir. The most common isolated symptom of a hypersensitivity reaction was a skin rash. Moreover, on very rare occasions hypersensitivity reactions have been reported in patients who have restarted therapy, and who had no preceding symptoms of a hypersensitivity reaction. In both cases if a decision is made to restart abacavir this must be done in a setting where medical assistance is readily available.

- Essential patient information.

Prescribers must ensure that patients are fully informed regarding the following information on the hypersensitivity reaction:

- Patients must be made aware of the possibility of a hypersensitivity reaction to abacavir as in MYLAMBA that may result in a life-threatening reaction or death.
- Patients developing signs or symptoms possibly linked with a hypersensitivity reaction **MUST CONTACT** their doctor **IMMEDIATELY**.
- Patients who are hypersensitive to abacavir should be reminded that they must never take the fixed-dose combination of MYLAMBA tablets or any other medicinal product containing abacavir again.
- In order to avoid restarting abacavir, patients who have experienced a hypersensitivity reaction should dispose of their remaining fixed-dose combination of MYLAMBA tablets in their possession in accordance with the local requirements and ask their doctor or pharmacist for advice.
- Patients who have stopped the fixed-dose combination of MYLAMBA tablets for any reason, and particularly due to possible adverse reactions or illness, must be advised to contact their doctor before restarting.
- Patients should be advised of the importance of taking the fixed-dose combination of MYLAMBA tablets regularly.
- Each patient should be reminded to read the Patient Information Leaflet included in the fixed-dose combination of MYLAMBA tablets package.
- They should be reminded of the importance of removing the Alert Card included in the package and keeping it with them at all times.

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

MYLAMBA constitutes abacavir (as sulfate) and lamivudine in one film-coated tablet.

Each film-coated tablet contains:

Abacavir sulfate equivalent to abacavir 600 mg

Lamivudine 300 mg

Sugar free

For full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM

Film-coated tablets.

Yellow coloured, biconvex, film-coated tablet, debossed with "M157" on one side and plain on the other side.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

MYLAMBA is a fixed-dose combination of two nucleoside analogues (abacavir and lamivudine). It is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents from 12 years of age. ^(1, 2)

4.2 Posology and method of administration

Posology:

Patients should be stabilised on individual medicines before being switched over to MYLAMBA. Therapy should be initiated by a medical practitioner experienced in the management of HIV infection. MYLAMBA should not be administered to adults or adolescents who weigh less than 40 kg because it is a fixed-dose tablet that cannot be dose reduced. ^(1, 2)

MYLAMBA can be taken with or without food. ^(1, 2)

Adults and adolescents: The recommended dose of MYLAMBA in adults and adolescents is one tablet once daily. ^(1, 2)

Special Populations

MYLAMBA is a fixed-dose tablet and should not be prescribed for patients requiring dosage adjustments, such as those with creatinine clearance less than 50 ml/min or with mild hepatic impairment. Separate preparations of abacavir or lamivudine should be administered in cases where discontinuation or dose adjustment is indicated. In these cases the medical practitioner should refer to the individual product information for these medicines. ^(1, 2)

Children:

MYLAMBA is not recommended for treatment of children as the necessary dose adjustment cannot be made. For these patients other fixed dose formulations are available. ^(1, 2)

Elderly:

The pharmacokinetics of abacavir and lamivudine have not been studied in patients over 65 years of age and consideration must be given to the greater frequency of decreased hepatic, renal and cardiac function; concomitant medicines or disease. ^(1, 2)

Renal impairment:

Whilst no dosage adjustment of abacavir is necessary in patients with renal dysfunction, a dose reduction of lamivudine is required due to decreased clearance. MYLAMBA is not recommended for use in patients with a creatinine clearance less than 50 ml/min.

Hepatic impairment:

A dose reduction of abacavir is likely to be required for patients with mild hepatic impairment. As dose reduction is not possible with MYLAMBA the separate preparations should be used when judged necessary. MYLAMBA must not be used in patients with moderate and severe hepatic impairment (see *section 5.2* Pharmacokinetic properties).

4.2 Contraindications

MYLAMBA is contraindicated in:

- Patients with known hypersensitivity to abacavir, lamivudine or to any of the excipients (see section 6.1).
- Patients with abnormally low neutrophil counts ($< 0,75 \times 10^9/l$) (see section 4.4).
- Patients with abnormally low haemoglobin levels ($< 7,5$ g/dl or 4,65 mmol/l) (see section 4.4).
- Patients with severe hepatic impairment.
- Patients with severe renal impairment.
- Patients who are receiving treatment with emtricitabine.
- Children below 12 years of age (weighing less than 40 kg) as the necessary dose adjustment cannot be made.

4.4 Special warnings and precautions for use

Patients who develop a hypersensitivity reaction must discontinue MYLAMBA and MUST not be re-challenged with MYLAMBA (see section 4.4).

Hypersensitivity to abacavir (see Section 4.8 Undesirable effects):

The special warnings and precautions relevant to both abacavir and lamivudine are included in this section. There are no additional precautions and warnings relevant to MYLAMBA. Hypersensitivity to abacavir (see section 4.8):

In clinical studies, approximately 5 % of subjects receiving abacavir developed a hypersensitive reaction, which in rare cases has proved fatal. Hypersensitivity is characterised by the appearance of symptoms indicating multi-organ/body-system involvement.

Patients who develop a hypersensitivity reaction must discontinue MYLAMBA and MUST NOT be rechallenged with MYLAMBA or any other product containing abacavir (see section 1 NAME OF MEDICINE - Boxed warning).

Lactic acidosis/severe hepatomegaly with steatosis:

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of lamivudine alone or in combination, in the treatment of HIV infection. ⁽²⁾

Long-term use of MYLAMBA can result in potentially fatal lactic acidosis. Symptomatic hyperlactataemia and lactic acidosis are uncommon. Clinical features are non-specific, and include nausea, vomiting, abdominal pain, dyspnoea, fatigue and weight loss. Suspicious biochemical features include raised

transaminases, raised lactate dehydrogenase (LDH) and/or creatine kinase. In patients with suspicious symptoms of biochemistry, measure the venous lactate level (normal < 2 mmol/l) and respond as follows:

Lactate 2-5 mmol/l: monitor regularly and be alert for clinical signs

Lactate 5-10 mmol/l without symptoms, monitor closely

Lactate 5-10 mmol/l with symptoms: STOP all therapy. Exclude other causes e.g. sepsis, uraemia, diabetic ketoacidosis, thyrotoxicosis, lymphoma

Lactate > 10 mmol/l: STOP all therapy (80 % mortality in case studies)

Diagnosis of lactic acidosis is confirmed by demonstrating metabolic acidosis with an increased anion gap and raised lactate level. Therapy should be stopped in any patient with a raised lactate level. Blood for lactate assay should be heparinised and stored on ice. After recovery, NRTIs should be avoided. Seek expert advice on medicine selection. The above lactate values may not be applicable to paediatric patients. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of MYLAMBA alone or in combination.

Caution should be exercised when administering MYLAMBA to any patient (particularly obese women) with hepatomegaly, hepatitis or other known risk factors of liver disease and hepatic steatosis (including certain medicinal products and alcohol). Patients co-infected with hepatitis C and treated with alpha interferon and ribavirin may constitute a special risk. Patients at increased risk should be followed closely. ^(1,2)

Mitochondrial dysfunction:

Observational studies have shown an association between myocardial infarction and the use of abacavir. Those studied were mainly antiretroviral experienced patients. Data from clinical trials showed limited numbers of myocardial infarction and could not exclude a small increase in risk. Overall the available data from observational cohorts and from randomised trials show some inconsistency so can neither confirm nor refute a causal relationship between abacavir treatment and the risk of myocardial infarction. To date, there is no established biological mechanism to explain a potential increase in risk. When prescribing MYLAMBA, action should be taken to try to minimize all modifiable risk factors (e.g. smoking, hypertension, and hyperlipidaemia).

Pancreatitis:

Pancreatitis has been observed in some patients receiving MYLAMBA. Pancreatitis must be considered whenever a patient develops abdominal pain, nausea, vomiting or elevated biochemical markers. Discontinue use of MYLAMBA until diagnoses of pancreatitis is excluded.

Lipodystrophy and metabolic abnormalities:

Combination antiretroviral therapy has been associated with the redistribution of body fat (lipodystrophy) in HIV patients. The long-term consequences of these events are currently unknown. Knowledge about the mechanism is incomplete. A connection between visceral lipomatosis and protease inhibitors (PIs) and lipodystrophy and nucleoside reverse transcriptase inhibitors (NRTIs) has been hypothesised. A higher risk of lipodystrophy has been associated with individual factors such as older age, and with medicine related factors such as longer

duration of antiretroviral treatment and associated metabolic disturbances. Clinical examination should include evaluation for physical signs of fat redistribution. Consideration should be given to the measurement of fasting serum lipids and blood glucose. Lipid disorders should be managed as clinically appropriate.

Immune Reconstitution Inflammatory Syndrome:

In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and *Pneumocystis jirovecii* pneumonia. Any inflammatory symptoms should be evaluated and treatment instituted when necessary.

Osteonecrosis:

Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART). Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.

Patients co-infected with hepatitis B or C virus:

If lamivudine is being used concomitantly for the treatment of HIV and HBV,

additional information relating to the use of lamivudine in the treatment of hepatitis B infection can be found in the Product Information of such medicines.

The safety and efficacy of MYLAMBA has not been established in patients with significant underlying liver disorders. MYLAMBA is contraindicated in patients with severe hepatic impairment.

Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse reactions. In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicines.

If MYLAMBA is discontinued in patients co-infected with hepatitis B virus, periodic monitoring of both liver function tests and markers of HBV replication is recommended, as withdrawal of lamivudine may result in an acute exacerbation of hepatitis (see the Product Information for such medicines).

Patients with pre-existing liver dysfunction, including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy, and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered. Caution is advised when used in patients with hepatitis B.

Myocardial Infarction:

Observational studies have shown an association between myocardial infarction and the use of abacavir. Those studied were mainly antiretroviral experienced patients. Data from clinical trials showed limited numbers of myocardial infarction and could not exclude a small increase in risk. Overall the available data from

observational cohorts and from randomised trials show some inconsistency so can neither confirm nor refute a causal relationship between abacavir treatment and the risk of myocardial infarction. To date, there is no established biological mechanism to explain a potential increase in risk. When prescribing MYLAMBA, action should be taken to try to minimize all modifiable risk factors (e.g. smoking, hypertension, and hyperlipidaemia).

Opportunistic infections:

Patients should be advised that MYLAMBA or any other antiretroviral therapy does not cure HIV infection and that they may still develop opportunistic infections and other complications of HIV infection. Therefore patients should remain under close clinical observation by medical practitioners experienced in the treatment of these associated HIV diseases. In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.

Transmission of infection:

Patients should be advised that current antiretroviral therapy, including MYLAMBA, has not been proven to prevent the risk of transmission of HIV to others through sexual contact or blood contamination. Appropriate precautions should continue to be taken. Combination antiretroviral therapy has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin resistance; hyperglycaemia and hyperlactataemia.

Risk of virological failure:

Triple nucleoside therapy:

There have been reports of a high rate of virological failure, and of emergence of resistance at an early stage when abacavir and lamivudine were combined with tenofovir disoproxil fumarate as a once daily regimen.

4.5 Interaction with other medicines and other forms of interaction

MYLAMBA contains abacavir and lamivudine therefore any interactions identified for these individually are relevant to MYLAMBA. Clinical studies have shown that there are no clinically significant interactions between abacavir and lamivudine.

Abacavir and lamivudine are not significantly metabolised by cytochrome P450 enzymes (such as CYP 3A4, CYP 2C9 or CYP 2D6) nor do they inhibit or induce this enzyme system. Therefore, there is little potential for interactions with antiretroviral protease inhibitors, non- nucleosides and other medicinal products metabolised by major P450 enzymes. The interactions listed below should not be considered exhaustive but are representative of the classes of medicines where caution should be exercised.

Interactions relevant to abacavir:

Potent enzymatic inducers such as rifampicin, phenobarbital and phenytoin may via their action on UDP-glucuronyltransferases slightly decrease the plasma concentrations of abacavir.

The metabolism of abacavir is altered by concomitant consumption of ethanol resulting in an increase in AUC of abacavir of about 41 %. These findings are not considered clinically significant. Abacavir has no effect on the metabolism of ethanol.

Retinoid compounds are eliminated via alcohol dehydrogenase. Interaction with

abacavir is possible but has not been studied.

In a pharmacokinetic study, co-administration of 600 mg abacavir twice daily with methadone showed a 35 % reduction in abacavir C_{max} and a 1 hour delay in t_{max} , but the AUC was unchanged. The changes in abacavir pharmacokinetics are not considered clinically relevant. In this study, abacavir increased the mean methadone systemic clearance by 22 %. The induction of metabolising enzymes cannot therefore be excluded. Patients being treated with methadone and abacavir should be monitored for evidence of withdrawal symptoms indicating under dosing, as occasionally methadone re-titration may be required.

Interactions relevant to lamivudine:

The likelihood of metabolic interactions with lamivudine is low due to limited metabolism and plasma protein binding, and almost complete renal clearance. The possibility of interactions with other medicinal products administered concurrently with MYLAMBA should be considered, particularly when the main route of elimination is active renal secretion, especially via the cationic transport system e.g. trimethoprim. Other medicinal products (e.g. ranitidine, cimetidine) are eliminated only in part by this mechanism and were shown not to interact with lamivudine. The nucleoside analogues (e.g. zidovudine and didanosine) are not metabolised by this mechanism and are unlikely to interact with lamivudine.

Administration of trimethoprim/sulfamethoxazole 160 mg/800 mg results in a 40 % increase in lamivudine exposure, because of the trimethoprim component. However, unless the patient has renal impairment, no dose adjustment of lamivudine is necessary. The pharmacokinetics of trimethoprim or sulfamethoxazole are not affected. When concomitant administration with cotrimoxazole is warranted, patients should be monitored clinically. Co-

administration of MYLAMBA with high doses of co-trimoxazole for the treatment of *Pneumocystis jirovecii* pneumonia (PCP) and toxoplasmosis should be avoided.

Co-administration of lamivudine with intravenous ganciclovir or foscarnet is not recommended until further information is available.

Zalcitabine: Lamivudine may inhibit the intracellular phosphorylation of zalcitabine when the two medicinal products are used together. MYLAMBA is therefore not recommended to be used in combination with zalcitabine..

4.6 Fertility, pregnancy and lactation

Pregnancy

MYLAMBA is not recommended during pregnancy. The safety of abacavir and lamivudine in human pregnancy has not been established. Studies with abacavir and lamivudine in animals have shown reproductive toxicity.

Breast-feeding

It is recommended that HIV-infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV. Lamivudine is excreted in human milk at similar concentrations to those found in serum. It is expected that abacavir will also be secreted into human milk, although this has not been confirmed. It is therefore recommended that mothers do not breast-feed their babies while receiving treatment with MYLAMBA.

Mitochondrial dysfunction: nucleoside and nucleotide analogues have been demonstrated in vitro and in vivo to cause a variable degree of mitochondrial damage. There have been reports of mitochondrial dysfunction in HIV-negative

infants exposed in utero and/or post-natally to nucleoside analogues. The main adverse reactions reported are haematological disorders (anaemia, neutropenia), metabolic disorders (hyperlactataemia, hyperlipidaemia). These reactions are often transitory. Some late-onset neurological disorders have been reported (hypertonia, convulsion, abnormal behaviour). Whether the neurological disorders are transient or permanent is currently unknown. Any child exposed in utero to nucleoside and nucleotide analogues, even HIV-negative children, should have clinical and laboratory follow-up and should be fully investigated for possible mitochondrial dysfunction in case of relevant signs or symptoms. ⁽²⁾

4.7 Effects on ability to drive and use machines

No studies on the effects on ability to drive and use machines have been performed. Nevertheless, the clinical status of the patient and the adverse reaction profile of should be borne in mind when considering the patient's ability to drive or operate machinery.

4.8 Undesirable effects

a) Summary of adverse effects

In clinical studies approximately 5 % of subjects receiving abacavir developed hypersensitivity reactions.

Some hypersensitivity reactions were life-threatening and resulted in fatal outcome despite taking precautions. This reaction is characterised by the appearance of symptoms indicating multi-organ/body-system involvement.

Almost all patients developing hypersensitivity reactions will have fever and/or rash (usually maculopapular or urticarial) as part of the syndrome, however reactions have occurred without rash or fever.

The signs and symptoms of this hypersensitivity reaction are listed below.

Those reported in at least of 10 % of patients with hypersensitivity reactions are in bold text:

b) Tabulated list of adverse reactions

Skin	Rash (usually maculopapular or urticarial)
<i>Gastrointestinal tract</i>	Nausea, vomiting, diarrhoea, abdominal pain , mouth ulceration
<i>Respiratory tract</i>	Dyspnoea, cough , sore throat, adult respiratory distress syndrome, respiratory failure
<i>Miscellaneous</i>	Fever, lethargy, malaise , oedema, lymphadenopathy, hypotension, conjunctivitis, anaphylaxis
<i>Neurological/Psychiatry</i>	Headache , paraesthesia
<i>Haematological</i>	Lymphopenia

<i>Liver/pancreas</i>	Elevated liver function tests , hepatitis, hepatic failure
<i>Musculoskeletal</i>	Myalgia, rarely myolysis, arthralgia, elevated creatine phosphokinase
<i>Urology</i>	Elevated creatinine, renal failure

Some patients with hypersensitivity reactions were initially thought to have gastroenteritis, respiratory disease (pneumonia, bronchitis, pharyngitis) or a flu-like illness. This delay in diagnosis of hypersensitivity has resulted in abacavir being continued or re-introduced, leading to more severe hypersensitivity reactions or death. Therefore, the diagnosis of hypersensitivity reaction should be carefully considered for patients presenting with symptoms of these diseases.

Symptoms usually appeared within the first six weeks (median time to onset 11 days) of initiation of treatment with abacavir, although these reactions may occur at any time during therapy. Close medical supervision is necessary during the first two months, with consultations every two weeks.

It is likely that intermittent therapy may increase the risk of developing sensitisation and therefore occurrence of clinically significant

hypersensitivity reactions. Consequently, patients should be advised of the importance of taking MYLAMBA regularly.

Restarting abacavir following a hypersensitivity reaction results in a prompt return of symptoms within hours. This recurrence of the hypersensitivity reaction is usually more severe than on initial presentation, and may include life-threatening hypotension and death.

Regardless of their HLA-B*5701 status, patients who develop this hypersensitivity reaction must discontinue MYLAMBA and must never be rechallenged with MYLAMBA, or any other medicinal product containing abacavir.

To avoid a delay in diagnosis and minimise the risk of a life-threatening hypersensitivity reaction, abacavir must be permanently discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible (respiratory diseases, flu-like illness, gastroenteritis or reactions to other medicines).

Hypersensitivity reactions with rapid onset, including life-threatening reactions have occurred after restarting abacavir in patients who had only one of the key symptoms of hypersensitivity (skin rash, fever, gastrointestinal, respiratory or constitutional symptoms such as lethargy and malaise) prior to stopping abacavir. The most common isolated symptom of a hypersensitivity reaction was a skin rash. Moreover, on very

rare occasions hypersensitivity reactions have been reported in patients who have restarted therapy and who had no preceding symptoms of a hypersensitivity reaction. In both cases, if a decision is made to restart abacavir, as in MYLAMBA, this must be done in a setting where medical assistance is readily available.

Each patient must be warned about this hypersensitivity reaction to abacavir.

Many of the adverse reactions listed in the table below occur commonly (nausea, vomiting, diarrhoea, fever, lethargy, rash) in patients with abacavir hypersensitivity. Therefore, patients with any of these symptoms should be carefully evaluated for the presence of this hypersensitivity reaction. If MYLAMBA has been discontinued in patients due to experiencing any one of these symptoms and a decision is made to restart a medicinal product containing abacavir, this must be done in a setting where medical assistance is readily available. Very rarely cases of erythema multiforme, Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported where abacavir hypersensitivity could not be ruled out. In such cases medicinal products containing abacavir, as in MYLAMBA, should be permanently discontinued.

The adverse reactions considered at least possibly related to abacavir or lamivudine are listed by body system, organ class and absolute frequency.

Body system	Abacavir	Lamivudine

Blood and lymphatic systems disorders		<i>Less frequent:</i> neutropenia and anaemia (both occasionally severe), thrombocytopenia, pure red cell aplasia
Immune system disorders	<i>Frequent:</i> hypersensitivity	
Metabolism and nutrition disorders	<i>Frequent:</i> anorexia, hyperlactataemia <i>Less frequent:</i> lactic acidosis, redistribution/accumulation of body fat	<i>Frequent:</i> hyperlactataemia, <i>Less frequent:</i> lactic acidosis, redistribution/accumulation of body fat
Nervous system disorders	<i>Frequent :</i> headache	<i>Frequent:</i> headache, insomnia <i>Less frequent:</i> peripheral neuropathy (or paraesthesia)

Respiratory, thoracic and mediastinal disorders		<i>Frequent:</i> cough, nasal symptoms
Gastrointestinal disorders	<i>Frequent :</i> nausea, vomiting, diarrhoea <i>Less frequent :</i> pancreatitis	<i>Frequent:</i> nausea, vomiting, abdominal pain or cramps, diarrhoea <i>Less frequent:</i> rises in serum amylase, pancreatitis
Hepatobiliary disorders		<i>Less frequent:</i> transient rises in liver enzymes (AST, ALT), hepatitis
Skin and subcutaneous tissue disorders	<i>Frequent:</i> rash (without systemic symptoms) <i>Less frequent:</i> erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis	<i>Frequent:</i> rash, alopecia

Musculoskeletal and connective tissue disorders		<i>Frequent</i> : arthralgia, muscle disorders <i>Less frequent</i> : rhabdomyolysis
General disorders and administration site conditions	<i>Frequent</i> : fever, lethargy, fatigue	<i>Frequent</i> : fatigue, malaise, fever

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Health care providers are asked to report any suspected adverse reactions to SAHPRA via the “**6.04 Adverse Drug Reactions Reporting Form**”, found online under SAHPRA’s publications:

<https://www.sahpra.org.za/Publications/Index/8>

4.9 Overdose

Symptoms and Signs:

No specific symptoms or signs have been identified following acute overdose with abacavir or lamivudine, apart from those listed as side-effects.

Treatment:

If overdose occurs the patient should be monitored for evidence of toxicity, and standard supportive treatment applied as necessary. Since lamivudine is dialysable, continuous haemodialysis could be used in the treatment of overdose, although this has not been studied. It is not known whether abacavir can be removed by peritoneal dialysis or haemodialysis.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antivirals for systemic use, antivirals for treatment of HIV infections, combinations. ATC code: J05AR02.

Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs), and are potent selective inhibitors of HIV-1 and HIV-2. All two medicinal products are metabolised sequentially by intracellular kinases to the respective 5'-triphosphate (TP).

Lamivudine-TP, carbovir-TP (the active triphosphate form of abacavir), are substrates for and competitive inhibitors of HIV reverse transcriptase (RT). However, their main antiviral activity is through incorporation of the monophosphate form into the viral DNA chain, resulting in chain termination. Abacavir, lamivudine triphosphates show significantly less affinity for host cell DNA polymerases.

Lamivudine has been shown to be highly synergistic with zidovudine, inhibiting the replication of HIV in cell culture. Abacavir shows synergy in vitro in combination with amprenavir, nevirapine and zidovudine. It has been shown to be additive in combination with didanosine, stavudine and lamivudine.

In vitro resistance:

HIV-1 resistance to lamivudine involves the development of a M184I or, more commonly, M184V amino acid change close to the active site of the viral RT.

Abacavir-resistant isolates of HIV-1 have been selected in vitro and are associated with specific genotypic changes in the RT codon region (codons M184V, K65R, L74V and Y115F). Viral resistance to abacavir develops relatively slowly in vitro, requiring multiple mutations for a clinically relevant increase in EC50 over wild-type virus.

In vivo resistance (Therapy-naïve patients):

The M184V or M184I variants arise in HIV-1 infected patients treated with lamivudine- containing antiretroviral therapy.

In vivo resistance (Therapy experienced patients):

The M184V or M184I variants arise in HIV-1 infected patients treated with lamivudine- containing antiretroviral therapy and confer high-level resistance to lamivudine.

Clinically significant reduction of susceptibility to abacavir has been demonstrated in clinical isolates of patients with uncontrolled viral replication, who have been pre-treated with and are resistant to other nucleoside inhibitors.

Phenotypic resistance and cross-resistance:

Zidovudine, didanosine, stavudine and tenofovir maintain their antiretroviral activities against such HIV-1 variants. The presence of M184V with K65R does

give rise to cross-resistance between abacavir, tenofovir, didanosine and lamivudine, and M184V with L74V gives rise to cross-resistance between abacavir, didanosine and lamivudine. The presence of M184V with Y115F gives rise to cross-resistance between abacavir and lamivudine. Appropriate use of abacavir can be guided using currently recommended resistance algorithms.

Cross-resistance between abacavir or lamivudine and antiretrovirals from other classes e.g. protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) is unlikely.

5.2 Pharmacokinetic properties

There is no clinically significant food effect observed between administrations of abacavir/lamivudine (FDC) in the fasted or fed state. These results indicate that FDC can be taken with or without food. The pharmacokinetic properties of lamivudine and abacavir are described below.

Absorption:

Abacavir and lamivudine are well absorbed from the gastro-intestinal tract following oral administration. The absolute bioavailability of oral abacavir and lamivudine in adults is about 83 % and 80 - 85 % respectively. The mean time to maximal serum concentrations (t_{max}) is about 1,5 hours and 1,0 hour for abacavir and lamivudine, respectively.

Following a single dose of 600 mg of abacavir, the mean (CV) C_{max} is 4,26 $\mu\text{g/ml}$ (28 %) and the mean (CV) AUC is 11,95 $\mu\text{g.h/ml}$ (21 %). Following multiple-dose oral administration of lamivudine 300 mg once daily for seven days, the mean (CV) steady-state C_{max} is 2,04 $\mu\text{g/ml}$ (26 %) and the mean (CV) AUC₂₄ is 8,87 $\mu\text{g.h/ml}$

(21 %).

Distribution:

Intravenous studies with abacavir and lamivudine showed that the mean apparent volume of distribution is 0,8 and 1,3 l/kg respectively. Plasma protein binding studies in vitro indicate that abacavir binds only low to moderately (~ 49 %) to human plasma proteins at therapeutic concentrations. Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited plasma protein binding in vitro (< 36 %). This indicates a low likelihood for interactions with other medicinal products through plasma protein binding displacement.

Data show that abacavir and lamivudine penetrate the central nervous system (CNS) and reach the cerebrospinal fluid (CSF). Studies with abacavir demonstrate a CSF to plasma AUC ratio of between 30 to 44 %. The observed values of the peak CSF concentrations are 9 fold greater than the IC50 of abacavir of 0,08 µg/ml or 0,26 µM when abacavir is given at 600 mg twice daily. The mean ratio of CSF/serum lamivudine concentrations 2 - 4 hours after oral administration was approximately 12 %. The true extent of CNS penetration of lamivudine and its relationship with any clinical efficacy is unknown.

Metabolism:

Abacavir is primarily metabolised by the liver with approximately 2 % of the administered dose being renally excreted, as unchanged compound. The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5'-carboxylic acid and 5'-glucuronide which account for about 66 % of the administered dose. These metabolites are excreted in the

urine.

Metabolism of lamivudine is a minor route of elimination. Lamivudine is predominately cleared by renal excretion of unchanged lamivudine. The likelihood of metabolic interactions with lamivudine is low due to the small extent of hepatic metabolism (5 - 10 %).

Elimination:

The mean half-life of abacavir is about 1,5 hours. Following multiple oral doses of abacavir 300 mg twice a day there is no significant accumulation of abacavir. Elimination of abacavir is via hepatic metabolism with subsequent excretion of metabolites primarily in the urine. The metabolites and unchanged abacavir account for about 83 % of the administered abacavir dose in the urine. The remainder is eliminated in the faeces.

The observed lamivudine half-life of elimination is 5 to 7 hours. The mean systemic clearance of lamivudine is approximately 0,32 l/h/kg, predominantly by renal clearance (> 70 %) via the organic cationic transport system.

Pharmacokinetics in Special Patient Groups:

Hepatically impaired:

There are no data available on the use of DUMIVA in hepatically impaired patients.

Pharmacokinetic data has been obtained for abacavir and lamivudine alone.

Abacavir is metabolised primarily by the liver. The pharmacokinetics of abacavir have been studied in patients with mild hepatic impairment (Child-Pugh score 5-6) receiving a single 600 mg dose. The results showed that there was a mean increase of 1,89-fold in the abacavir AUC, and 1,58-fold in the half-life of abacavir.

Dosage reduction of abacavir is likely to be required in patients with mild hepatic impairment. The separate preparations of abacavir should therefore be used to treat these patients. The pharmacokinetics of abacavir have not been studied in patients with moderate or severe hepatic impairment. Plasma concentrations of abacavir are expected to be variable and substantially increased in these patients. DUMIVA is therefore contra-indicated in patients with moderate to severe hepatic impairment.

Data obtained in patients with moderate to severe hepatic impairment show that lamivudine pharmacokinetics are not significantly affected by hepatic dysfunction.

Renal impairment:

Pharmacokinetic data have been obtained for lamivudine and abacavir alone. Abacavir is primarily metabolised by the liver with approximately 2 % of abacavir excreted unchanged in the urine. The pharmacokinetics of abacavir in patients with end-stage renal disease is similar to patients with normal renal function. Studies with lamivudine show that plasma concentrations (AUC) are increased in patients with renal dysfunction due to decreased clearance.

Dose reduction is required for patients with creatinine clearance of < 50 ml/min therefore the separate preparation of lamivudine should be used to treat these patients.

Elderly:

No pharmacokinetic data are available in patients over 65 years of age.

5.3 Preclinical safety data

With the exception of a negative in vivo rat micronucleus test, there are no data available on the effects of the combination of abacavir and lamivudine in animals.

Mutagenicity and carcinogenicity

Neither abacavir nor lamivudine were mutagenic in bacterial tests, but consistent with other nucleoside analogues, they inhibit cellular DNA replication in in vitro mammalian tests such as the mouse lymphoma assay. The results of an in vivo rat micronucleus test with abacavir and lamivudine in combination were negative. ⁽³⁾

Lamivudine has not shown any genotoxic activity in the in vivo studies at doses that gave plasma concentrations up to 40-50 times higher than clinical plasma concentrations. Abacavir has a weak potential to cause chromosomal damage both in vitro and in vivo at high tested concentrations. ⁽³⁾

The carcinogenic potential of a combination of abacavir and lamivudine has not been tested. In long-term oral carcinogenicity studies in rats and mice, lamivudine did not show any carcinogenic potential. Carcinogenicity studies with orally administered abacavir in mice and rats showed an increase in the incidence of malignant and non-malignant tumours. Malignant tumours occurred in the preputial gland of males and the clitoral gland of females of both species, and in rats in the thyroid gland of males and in the liver, urinary bladder, lymph nodes and the subcutis of females.

The majority of these tumours occurred at the highest abacavir dose of 330 mg/kg/day in mice and 600 mg/kg/day in rats. The exception was the preputial gland tumour which occurred at a dose of 110 mg/kg in mice. The systemic exposure at the no effect level in mice and rats was equivalent to 3 and 7 times the human systemic exposure during therapy. While the clinical relevance of these findings is unknown, these data suggest that a carcinogenic risk to humans is outweighed by the potential clinical benefit.

Repeat-dose toxicity

In toxicology studies abacavir was shown to increase liver weights in rats and monkeys. The clinical relevance of this is unknown. There is no evidence from clinical studies that abacavir is hepatotoxic. Additionally, autoinduction of abacavir metabolism or induction of the metabolism of other medicinal products hepatically metabolised has not been observed in man. Mild myocardial degeneration in the heart of mice and rats was observed following administration of abacavir for two years. The systemic exposures were equivalent to 7 to 24 times the expected systemic exposure in humans. The clinical relevance of this finding has not been determined.

Reproductive toxicology

In reproductive toxicity studies in animals, lamivudine and abacavir were shown to cross the placenta.

Lamivudine was not teratogenic in animal studies but there were indications of an increase in early embryonic deaths in rabbits at relatively low systemic exposures, comparable to those achieved in humans. A similar effect was not seen in rats even at very high systemic exposure.

Abacavir demonstrated toxicity to the developing embryo and foetus in rats, but not in rabbits. These findings included decreased foetal body weight, foetal oedema, and an increase in skeletal variations/malformations, early intra-uterine deaths and still births. No conclusion can be drawn with regard to the teratogenic potential of abacavir because of this embryo-foetal toxicity.

A fertility study in rats has shown that abacavir and lamivudine had no effect on male or female fertility.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core:

Colloidal silicon dioxide

Magnesium stearate

Microcrystalline cellulose

Sodium starch glycollate

Coating:

Opadry Yellow.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

24 months

6.4 Special precautions for storage

Store at or below 30 °C. Protect from light.

Store in the original container.

Keep the blisters in the outer carton until required for use.

Keep the container tightly closed.

6.5 Nature and contents of container

MYLAMBA is presented in the following:

High Density Polyethylene (HDPE) bottle pack (marketable pack) comprising of a round wide mouth white HDPE bottle with white opaque polypropylene (PP) screw

cap with aluminium induction sealing wad with a package insert in an outer carton.

Pack size of 28's or 30.

High Density Polyethylene (HDPE) bottle pack (marketable pack) comprising of a blue wide mouth blue opaque HDPE bottle with blue opaque polypropylene screw cap with aluminium induction sealing liner wad with a package insert in an outer carton. Pack size of 28's or 30. PVC/Aclar blister pack (marketable pack) comprises of clear, transparent, PVC film-coated with Aclar on one side (i.e. PVC/Aclar) and hard tempered aluminium foil (coated with VMCH heat seal lacquer) on other side with a package insert in an outer carton. Pack size of 28's or 30.*

*Not all packs may be marketed.

6.6 Special precautions for disposal and other handling

No special requirements.

7 HOLDER OF CERTIFICATE OF REGISTRATION

Mylan (Pty) Ltd

Building 6, Greenstone Hill Office Park

Emerald Boulevard

Modderfontein, 1645

Republic of South Africa

8 REGISTRATION NUMBER

55/20.2.8/0255

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

19 April 2022

10 DATE OF REVISION OF THE TEXT